Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Health officials are concerned millions of people with health issues aren't taking up vaccination offers as UK faces a triple ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Earlier this year, GSK said it would invest £200 million (around $260 million) in upgrades to its manufacturing network in ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

The Centers for Disease Control and Prevention is urging some people to get additional doses of the COVID-19 vaccine for ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an ...

Important information new parents need to know about Respiratory Syncytial Virus, or RSV. It comes around when the weather ...

While the risks associated with COVID-19 generally have decreased over time due to prior exposure to the vaccines and the virus, some people remain at elevated risk, such as the elderly and ...